Search

Your search keyword '"Vargas‐Madueno, Fernando"' showing total 9 results
Start Over Author "Vargas‐Madueno, Fernando"
9 results on '"Vargas‐Madueno, Fernando"'

1. Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.

Author

Andorsky, David Jacob, primary, Boccia, Ralph V., additional, Lash, Bradley Walter, additional, Vaidya, Rakhee, additional, Gandhi, Mitul, additional, Patel, Ameet, additional, Ibrahimi, Sami, additional, Vargas Madueno, Fernando Manuel, additional, Lee, Christina Y., additional, Naik, Seema, additional, Haydu, J. Erika, additional, Fesler, Mark, additional, Osei-Bonsu, Kojo, additional, Conte, Kristin, additional, Doerr, Thomas, additional, Bai, Yang, additional, Sacchi, Mariana, additional, and Sharman, Jeff Porter, additional

Published
2024
Full Text
View/download PDF

5. Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency.

Author

Vargas Madueno, Fernando Manuel, primary, Duan, Wenrui, additional, Diaz, Zuanel, additional, Diaz, John Paul, additional, Albrecht, Federico, additional, Venkatappa, Siddharta, additional, Schroeder, Eric Douglas, additional, Aparo, Santiago, additional, Yanek, Vanessa, additional, Walker, Gail, additional, and Villalona, Miguel, additional

Published
2018
Full Text
View/download PDF

6. The MD CaREs initiative: Tailoring oncology education to ethnically and culturally diverse students.

Author

Diaz, Zuanel, primary, Lupi, Carla, additional, Vargas Madueno, Fernando Manuel, additional, Roller, Barbra A., additional, Brewster, Cheryl, additional, Wells, Alan, additional, Ordonez, Jessica, additional, Suarez, Deborah, additional, Paez, Michael, additional, Boyd, Jeff, additional, Runowicz, Carolyn D., additional, and Villalona-Calero, Miguel Angel, additional

Published
2018
Full Text
View/download PDF

9. Unexpected Rasburicase-Induced Hemolysis in a Patient With Normal Glucose-6-Phosphate Dehydrogenase Activity.

Author

Musleh Ud Din S, Shan K, Rehman TU, Ivanov S, and Vargas-Madueno FM

Abstract

Tumor lysis syndrome (TLS) presents significant challenges in oncology, primarily due to metabolic complications such as hyperuricemia, which can lead to acute kidney injury. Rasburicase, a recombinant urate oxidase, is frequently employed to manage hyperuricemia in TLS patients. However, its use is an absolute contraindication in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of hemolysis. In this case, the patient developed hemolytic anemia post-rasburicase administration even though she had normal G6PD activity, which was confirmed on two separate occasions, including during an acute episode and 3 months later. This case is unique as it documents hemolytic anemia induced by rasburicase in a patient without G6PD deficiency, challenging current understandings of the drug's safety profile. It suggests the need for caution and thorough screening before rasburicase use, even in patients considered low risk for G6PD deficiency. The report highlights the importance of close monitoring for adverse effects and the potential for alternative mechanisms of rasburicase-induced hemolysis., Competing Interests: All authors have no conflict of interest to declare., (Copyright 2024, Musleh Ud Din et al.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results